Stool-based methylated syndecan-2 testing has a high positive predictive value in an average/increased-risk population: a multicenter retrospective study.

ABSTRACT:

Introduction

Stool DNA testing based on methylated syndecan-2 (mSDC2) is a potential novel non-invasive screening test for colorectal cancer (CRC). This study aimed to assess its positive predictive value (PPV) in real-world practice.

Methods

This study retrospectively recruited consecutive patients with positive stool DNA-based SDC2 methylation tests from 18 hospitals between November 2016 and July 2021. Included patients were classified into the average-risk equivalent or increased-risk population and the previous-negative-colonoscopy or no-previous-colonoscopy groups. Multivariate logistic regression was conducted to investigate the risk factors that affect the detection of advanced colorectal neoplasia (ACN) in patients with a positive mSDC2 test. The primary outcome was

SUBMITTER: Huang X 

PROVIDER: S-EPMC12360836 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature